Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (IN... von Wu, Yi-Long, Cheng, Ying, Zhou, Jianying, Lu, Shun, Zhang, Yiping, Zhao, Jun, Kim, Dong-Wan, Soo, Ross Andrew, Kim, Sang-We, Pan, Hongming, Chen, Yuh-Min, Chian, Chih-Feng, Liu, Xiaoqing, Tan, Daniel Shao Weng, Bruns, Rolf, Straub, Josef, Johne, Andreas, Scheele, Jürgen, Park, Keunchil, Yang, James Chih-Hsin, Liu, Zhe, Chen, Xi, Wang, Mengzhao, Yu, Shiying, Zhang, Helong, Fang, Jian, Li, Wei, Yang, Chih-Hsin, Chang, Gee-Chen, Hsia, Te-Chun, Yang, Cheng-Ta, Wang, Chin-Chou, Cho, Byoung Chul, Lee, Ki Hyeong, Kim, Young-Chul, An, Ho Jung, Woo, In Sook, Cho, Jae Yong, Shin, Sang Won, Lee, Jong-Seok, Kim, Joo-Hang, Yoo, Seung Soo, Kato, Terufumi, Shinagawa, Naofumi, Tan, Shao Weng Daniel, Ngo, Lynette Si-Mien, Ratnavelu, Kananathan, Ahmad, Azura Rozila, Liam, Chong Kin, de Marinis, Filippo, Tassone, Pierfrancesco, Molla, Amelia Insa, Calles Blanco, Antonio, Lazaro Quintela, Martin Emilio, Felip Font, Enriqueta, Dingemans, Anne-Marie, Bui, Lynne

Volltext

Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer von Su, Kang-Yi, Chen, Hsuan-Yu, Li, Ker-Chau, Kuo, Min-Liang, Yang, James Chih-Hsin, Chan, Wing-Kai, Ho, Bing-Ching, Chang, Gee-Chen, Shih, Jin-Yuan, Yu, Sung-Liang, Yang, Pan-Chyr

Volltext

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected P... von FUKUOKA, Masahiro, WU, Yi-Long, DUFFIELD, Emma L, RUKAZENKOV, Yuri, SPEAKE, Georgina, HAIYI JIANG, ARMOUR, Alison A, TO, Ka-Fai, CHIH-HSIN YANG, James, MOK, Tony S. K, THONGPRASERT, Sumitra, SUNPAWERAVONG, Patrapim, LEONG, Swan-Swan, SRIURANPONG, Virote, CHAO, Tsu-Yi, NAKAGAWA, Kazuhiko, CHU, Da-Tong, SAIJO, Nagahiro

Volltext

Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non―Small Cell Lung Cancer von WU, Jenn-Yu, YU, Chong-Jen, CHANG, Yeun-Chung, YANG, Chih-Hsin, SHIH, Jin-Yuan, YANG, Pan-Chyr

Volltext

Checkpoint Inhibitors in Metastatic EGFR-Mutated Non–Small Cell Lung Cancer—A Meta-Analysis von Lee, Chee Khoon, Man, Johnathan, Lord, Sally, Links, Matthew, Gebski, Val, Mok, Tony, Yang, James Chih-Hsin

Volltext

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma von Mok, Tony S, Wu, Yi-Long, Thongprasert, Sumitra, Yang, Jin-Ji, Yang, Chih-Hsin, Chu, Da-Tong, Saijo, Nagahiro, Sunpaweravong, Patrapim, Han, Baohui, Margono, Benjamin, Ichinose, Yukito, Nishiwaki, Yutaka, Ohe, Yuichiro, Chewaskulyong, Busyamas, Jiang, Haiyi, Duffield, Emma L, Watkins, Claire L, Armour, Alison A, Fukuoka, Masahiro

Volltext

Precision Management of Advanced Non-Small Cell Lung Cancer von Yang, Ching-Yao, Yang, James Chih-Hsin, Yang, Pan-Chyr

Volltext

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer von Jänne, Pasi A, Yang, James Chih-Hsin, Kim, Dong-Wan, Planchard, David, Ohe, Yuichiro, Ramalingam, Suresh S, Ahn, Myung-Ju, Kim, Sang-We, Su, Wu-Chou, Horn, Leora, Haggstrom, Daniel, Felip, Enriqueta, Kim, Joo-Hang, Frewer, Paul, Cantarini, Mireille, Brown, Kathryn H, Dickinson, Paul A, Ghiorghiu, Serban, Ranson, Malcolm

Volltext

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patient... von Lin, Yen‐Ting, Chen, Jin‐Shing, Liao, Wei‐Yu, Ho, Chao‐Chi, Hsu, Chia‐Lin, Yang, Ching‐Yao, Chen, Kuan‐Yu, Lee, Jih‐Hsiang, Lin, Zhong‐Zhe, Shih, Jin‐Yuan, Yang, James Chih‐Hsin, Yu, Chong‐Jen

Volltext

Cone-beam CT image quality improvement using Cycle-Deblur consistent adversarial networks (Cycle-Deblur GAN) for chest CT imaging in breast cancer patients von Tien, Hui-Ju, Yang, Hsin-Chih, Shueng, Pei-Wei, Chen, Jyh-Cheng

Volltext

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report von Yang, James Chih-Hsin, Shepherd, Frances A., Kim, Dong-Wan, Lee, Gyeong-Won, Lee, Jong Seok, Chang, Gee-Chen, Lee, Sung Sook, Wei, Yu-Feng, Lee, Yun Gyoo, Laus, Gianluca, Collins, Barbara, Pisetzky, Francesca, Horn, Leora

Volltext

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib von Bean, James, Brennan, Cameron, Shih, Jin-Yuan, Riely, Gregory, Viale, Agnes, Wang, Lu, Chitale, Dhananjay, Motoi, Noriko, Szoke, Janos, Broderick, Stephen, Balak, Marissa, Chang, Wen-Cheng, Yu, Chong-Jen, Gazdar, Adi, Pass, Harvey, Rusch, Valerie, Gerald, William, Huang, Shiu-Feng, Yang, Pan-Chyr, Miller, Vincent, Ladanyi, Marc, Yang, Chih-Hsin, Pao, William

Volltext

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases von Yang, James Chih-Hsin, Schuler, Martin, Popat, Sanjay, Miura, Satoru, Heeke, Simon, Park, Keunchil, Märten, Angela, Kim, Edward S.

Volltext

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study von Rudin, Charles M, Awad, Mark M, Navarro, Alejandro, Gottfried, Maya, Peters, Solange, Csőszi, Tibor, Cheema, Parneet K, Rodriguez-Abreu, Delvys, Wollner, Mirjana, Yang, James Chih-Hsin, Mazieres, Julien, Orlandi, Francisco J, Luft, Alexander, Gümüş, Mahmut, Kato, Terufumi, Kalemkerian, Gregory P, Luo, Yiwen, Ebiana, Victoria, Pietanza, M Catherine, Kim, Hye Ryun

Volltext

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib von Vishwanathan, Karthick, Dickinson, Paul A., So, Karen, Thomas, Karen, Chen, Yuh‐Min, De Castro Carpeño, Javier, Dingemans, Anne‐Marie C., Kim, Hye Ryun, Kim, Joo‐Hang, Krebs, Matthew G., Chih‐Hsin Yang, James, Bui, Khanh, Weilert, Doris, Harvey, R. Donald

Volltext

Phenotypic Heterogeneity in Patients with Mutations in the Mitochondrial Complex I Assembly Gene NDUFAF5 von Chen, Pin‐Shiuan, Lee, Ni‐Chung, Sung, Chieh‐Ju, Liu, Ya‐Wen, Weng, Wen‐Chin, Fan, Pi‐Chuan, Lee, Wang‐Tso, Chien, Yin‐Hsiu, Wu, Chao‐Szu, Sung, Yueh‐Feng, Tsai, Ming‐Chen, Lee, Yi‐Chung, Hsueh, Hsueh‐Wen, Fan, Sabrina Mai‐Yi, Wu, Meng‐Chen, Li, Hsun, Chen, Huan‐Yun, Lin, Han‐I, Ou‐Yang, Chih‐Hsin, Hwuh, Wuh‐Liang, Lin, Chin‐Hsien

Volltext

Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial von DE BOER, Richard H, ARRIETA, Oscar, LANGMUIR, Peter, MILENKOVA, Tsveta, READ, Jessica, VANSTEENKISTE, Johan F, YANG, Chih-Hsin, GOTTFRIED, Maya, CHAN, Valorie, RAATS, Johann, DE MARINIS, Filippo, ABRATT, Raymond P, WOLF, Jürgen, BLACKHALL, Fiona H

Volltext

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations von SEQUIST, Lecia V, YANG, James Chih-Hsin, SU, Wu-Chou, BENNOUNA, Jaafar, KATO, Terufumi, GORBUNOVA, Vera, KI HYEONG LEE, SHAH, Riyaz, MASSEY, Dan, ZAZULINA, Victoria, SHAHIDI, Mehdi, SCHULER, Martin, YAMAMOTO, Nobuyuki, O'BYRNE, Kenneth, HIRSH, Vera, MOK, Tony, GEATER, Sarayut Lucien, ORLOV, Sergey, TSAI, Chun-Ming, BOYER, Michael

Volltext

SOX4 transcriptionally regulates multiple SEMA3/plexin family members and promotes tumor growth in pancreatic cancer von Huang, Hsin-Yi, Cheng, Yu-Yao, Liao, Wei-Chih, Tien, Yu-Wen, Yang, Chih-Hsin James, Hsu, Su-Ming, Huang, Pei-Hsin

Volltext

Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response von WU, Jenn-Yu, WU, Shang-Gin, YANG, Chih-Hsin, GOW, Chien-Hung, CHANG, Yih-Leong, YU, Chong-Jen, SHIH, Jin-Yuan, YANG, Pan-Chyr

Volltext